![6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine in PDB entry 4c02, assembly 1, side view.](https://www.ebi.ac.uk/pdbe/static/entry/4c02_entity_4_side_image-200x200.png "Hetero dimeric assembly 1 of PDB entry <span class='highlight'>4c02</span> contains 1 copy of <span class='highlight'>6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine</span>. Side view.")
![6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine in PDB entry 4c02, assembly 1, top view.](https://www.ebi.ac.uk/pdbe/static/entry/4c02_entity_4_top_image-200x200.png "Hetero dimeric assembly 1 of PDB entry <span class='highlight'>4c02</span> contains 1 copy of <span class='highlight'>6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine</span>. Top view.")
Environment details NEW
TAK 1507 bound to chain A
The above 2D and 3D (Mol*) views of ligand interactions use quaternary structure derived from the PDB entry.
Please note:
Please note:
- Some chain IDs in the tooltip are followed by a number in square brackets. This number corresponds to the operation ID (mmCIF ‘oper_expression’) used to transform the chain.
- The structure seen in Mol* (3D view) was protonated using ChimeraX.
- Interactions were calculated using Arpeggio (see details for interaction types).
- The colour scheme used is consistent with Clustal X.